Linezolid in methicillin-resistant staphylococcus aureus nosocomial pneumonia: A randomized, controlled study

Clinical Infectious Diseases

Volumn 54, Issue 5, 2012, Pages 621-629

  Wunderink, Richard G ^a   Niederman, Michael S ^b   Kollef, Marin H ^c   Shorr, Andrew F ^d   Kunkel, Mark J ^e   Baruch, Alice ^e   McGee, William T ^f   Reisman, Arlene ^e   Chastre, Jean ^g  

^a NORTHWESTERN UNIVERSITY   (United States)

^b WINTHROP UNIVERSITY HOSPITAL   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e PFIZER INC   (United States)

^f BAYSTATE MEDICAL CENTER   (United States)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFTRIAXONE; CIPROFLOXACIN; LEVOFLOXACIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; VANCOMYCIN;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; AGED; ANEMIA; ARTICLE; BRAIN HEMORRHAGE; CHRONIC KIDNEY FAILURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; HEALTH CARE; HEART ATRIUM FIBRILLATION; HEPATITIS; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; HYPERKALEMIA; HYPERSENSITIVITY; INCIDENCE; INTENTION TO TREAT ANALYSIS; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; NEUTROPENIA; PERFORATION; PNEUMONIA; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; UREMIA;

ACETAMIDES; ADULT; AGED; ANTI-BACTERIAL AGENTS; CROSS INFECTION; FEMALE; HUMANS; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MIDDLE AGED; OXAZOLIDINONES; PNEUMONIA, STAPHYLOCOCCAL; TREATMENT OUTCOME;

EID: 84856937734     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir895     Document Type: Article

References (29)

1. Fridkin SK, Steward CD, Edwards JR, et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: project ICARE phase 2. Project Intensive Care Antimicrobial Resistance Epidemiology (ICARE) hospitals. Clin Infect Dis 1999; 29:245-52.
2. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996; 275:189-93.
3. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6:428-42.
4. Centers for Disease Control and Prevention. Guidelines for prevention of nosocomial pneumonia. MMWR Recomm Rep 1997; 46:1-79.
5. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2008; 46(Suppl 5):S378-85.
6. Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128:3854-62.
7. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 2007; 51: 3568-73.
8. Kawasaki S, Aoki N, Kikuchi H, et al. Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia? J Infect Chemother 2011; 17:640-5.
9. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
10. Klevens RM, Edwards JR, Tenover FC, McDonald LC,Horan T, Gaynes R. Changes in the epidemiology of methicillin-resistant Staphylococcus aureus in intensive care units in US hospitals, 1992-2003. Clin Infect Dis 2006; 42:389-91.
11. Kallen AJ, Mu Y, Bulens S, et al. Health care-associated invasive MRSA infections, 2005-2008. JAMA 2010; 304:641-8.
12. Rubinstein E, Cammarata S, Oliphant T, Wunderink R. Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32:402-12.
13. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH. Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-92.
14. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, KollefMH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124:1789-97.
15. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med 2004; 30: 388-94.
16. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
17. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011; 52:285-92.
18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute, 2005.
19. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
20. Pugin J. Clinical signs and scores for the diagnosis of ventilator-associated pneumonia. Minerva Anestesiol 2002; 68:261-5.
21. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35:549-56.
22. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. New York, NY: Wiley Interscience, 2002.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assn 1958; 53:457-81.
24. Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest 2010; 138:1356-62.
25. Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med 2010; 38: 1802-8.
26. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
27. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507-14.
28. Nguile-Makao M, Zahar JR, Francais A, et al. Attributable mortality of ventilator-associated pneumonia: respective impact of main characteristics at ICU admission and VAP onset using conditional logistic regression and multi-state models. Intensive Care Med 2010; 36:781-9.
29. Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33:1983-7.